Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S086 vs Sacubitril/Valsartan in HFrEF
NCT05553886Phase 3Recruiting
- Sponsor
- Shenzhen People's Hospital
- Start
- Dec 2021
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) (2 arms), sponsored by Shenzhen People's Hospital. Primary endpoint: Change in Left Ventricular Ejection Fraction from Baseline at 28 weeks. Started Dec 2021; status: recruiting.
02
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT05553886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05553886.